The FDA has approved Bristol Myers Squibb’s Opdualag, a combination immunotherapy for the treatment of unresectable or metastatic melanoma, the drugmaker said March 18.
Read the full post on Becker's Hospital Review - Healthcare News
FDA approves Bristol Myers’ immunotherapy for advanced melanoma
